SAN FRANCISCO, CALIFORNIA and TORONTO, ONTARIO--(Marketwire - Oct. 14, 2011) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home cardiology disease management services, has announced exciting new projections regarding the aggregate US "Remote Patient Monitoring" market which is expected to exceed $22 billion annually. In addition, PHM and DRM Ventures Inc. (DRM) (TSX VENTURE:DRM.P) are pleased to announce that they have completed their previously announced (July 11, 2011) financing with DRM.

According to a September 2011 report by healthcare market research firm Kalorama, the US remote patient monitoring market is expected to grow by 25% annually from $7.1 billion to $22.2 billion in 2015. The report, titled, "Remote and Wireless Patient Monitoring Markets," is based on annual reports, trade publications and interviews with industry executives.

"We are extremely excited by the potential opportunities of such a large market" commented Dr. Jaime Gerber, PHM's CEO. "While Coumadin® management is our initial market entry point, our long term strategy is to expand into other disease-management areas and it is very assuring to see the magnitude of possibilities."

"The 25% compounded annual market growth is huge and is being driven by widespread demand from both patients and physicians, as well as systemic shortages of cardiologists. I am reassured by these numbers that PHM has entered the right market at the right time with the right strategy," commented Dr. Jaime Gerber, PHM's CEO.

In light of these projections, PHM has completed a small private placement with DRM to help fuel its efforts to capture greater market share. DRM has been issued 4,264,706 common shares of PHM at a price of $0.164137926 per share for aggregate gross proceeds to PHM of $700,000. Each shareholder of DRM will receive 0.6511 shares of PHM for every one share of DRM held. Of the 4,264,706 common shares of PHM distributed to the shareholders of DRM, 1,009,205 will be deposited in escrow to DRM shareholders who held their shares in escrow. Shortly after the distribution of the shares, DRM expects to delist its common shares from the Exchange and complete a voluntary dissolution. All unexercised options and broker warrants to acquire shares of DRM will be cancelled upon completion of the return of capital and dissolution.

With the additional capital, PHM anticipates that it will have funding to acquire additional meters so it can continue to grow its existing patient base. Including the issuance of shares detailed in this news release, there are currently 64,419,086 shares of PHM issued and outstanding.

As a "capital pool company" pursuant to the rules of the TSX Venture Exchange (the Exchange), the financing is part of DRM's Qualifying Transaction. DRM received shareholder approval for the financing at its special meeting (the Meeting) of shareholders on October 5, 2011. At the Meeting, DRM shareholders also approved the distribution of the shares of PHM acquired by DRM in the financing to the shareholders of DRM on a pro-rata basis as a return of capital, and the subsequent delisting and dissolution of DRM.

Further information about PHM and DRM, including a copy of DRM's management information circular dated September 6, 2011 in connection with the Meeting, can be found online at [ www.sedar.com ].

About PHM

PHM is a healthcare services company focused on providing home-based monitoring services and supplies for cardiology patients. PHM's entry-point service monitors patients on blood thinner medications such as Coumadin® or warfarin. Medicare recently expanded reimbursement for this in-home service. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization to enroll patients in PST. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, increasing revenue to their clinic while providing a higher standard of care for patients. PHM plans to lever its position as a value-added service provider to expand into other home-based services for these patients and their referring physicians.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and DRM and anticipated events or results, are assumptions based on beliefs of PHM's and DRM's senior management as well as information currently available to it. The DRM Qualifying Transaction is subject to final Exchang approval. While these assumptions were considered reasonable by PHM and DRM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

This press release does not constitute and the subject matter hereof is not, an offer for sale or a solicitation of an offer to buy, in the United States or to any "U.S Person" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "1933 Act")) of any equity or other securities of PHM. The securities of PHM have not been registered under the 1933 Act and may not be offered or sold in the United States (or to a U.S. Person) absent registration under the 1933 Act or an applicable exemption from the registration requirements of the 1933 Act.

Contributing Sources

---

Market Wire